Pharmaceutical - Pharmaceutical, Boehringer Ingelheim

Filter

Popular Filters

1 to 25 of 184 results

FDA expands indication for Eliquis to treatment of DVT and PE

FDA expands indication for Eliquis to treatment of DVT and PE

22-08-2014

US pharma majors Bristol-Myers Squibb and Pfizer late yesterday said that the US Food and Drug Administration…

Boehringer IngelheimCardio-vascularEliquisPfizerPharmaceuticalPulmonary embolismRegulationUSA

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

21-08-2014

The asthma market in Brazil and Mexico currently faces severe coverage restrictions and, as the treatment…

Boehringer IngelheimBrazilGenentechMexicoNovartisPfizerPharmaceuticalRespiratory and PulmonarySpirivaXolair

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

19-08-2014

The US Food and Drug Administration yesterday granted tentative approval for Basaglar (insulin glargine…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyInsulin Glargine [rDNA origin] InjectionLantusPharmaceuticalRegulationUSA

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

15-08-2014

There was good news late yesterday for German family-owned pharma major Boehringer Ingelheim, when an…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivatiotropiumUS Food and Drug AdministrationUSA

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Boehringer Ingelheim acquires licensing rights for Artilysin technology

Boehringer Ingelheim acquires licensing rights for Artilysin technology

13-08-2014

Artilysin, a new and innovative technological approach in the fight against pathogenic and multi-resistant…

Antibiotics and Infectious diseasesArtilysinBoehringer IngelheimGermanyLicensingLysando AGPharmaceutical

Boehringer Ingelheim sees 1st-half sales fall, but overcomes challenges

Boehringer Ingelheim sees 1st-half sales fall, but overcomes challenges

12-08-2014

German family-owned pharma major Boehringer Ingelheim reported first-half 2014 results, showing that…

Boehringer IngelheimChronic obstructive pulmonary disease therapyFinancialGermanyPharmaceutical

OX-MPI project returned to Orexo

OX-MPI project returned to Orexo

08-08-2014

Swedish drug developer Orexo says that German family-owned pharma major Boehringer Ingelheim has decided…

Boehringer IngelheimGermanyLicensingOrexo ABPharmaceuticalProstaglandin ESweden

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

07-08-2014

With the recent approval of Jardiance (empagliflozin) in the USA, Eli Lilly and its partner, German family-owned…

Boehringer IngelheimDiabetesEli LillyEli Lilly and CompanyJanuviaJardianceMarkets & MarketingMerck & CoPharmaceuticalTradjenta

Medivir licenses RSV program from Boehringer Ingelheim

Medivir licenses RSV program from Boehringer Ingelheim

05-08-2014

Swedish drugmaker Medivir has entered a license agreement with German family-owned pharma major Boehringer…

Boehringer IngelheimGlobalHuman respiratory syncytial virusLicensingMedivirMononegaviralesPharmaceuticalRespiratory and PulmonaryViral diseases

US FDA approves Jardiance for adults with type 2 diabetes

US FDA approves Jardiance for adults with type 2 diabetes

02-08-2014

The US Food and Drug Administration on Friday approved Jardiance (empagliflozin) tablets as an adjunct…

Boehringer IngelheimDiabetesEli LillyEuropeGermanyJardiancePharmaceuticalRegulationUSA

FDA approves Boehringer’s Striverdi Respimat for COPD

FDA approves Boehringer’s Striverdi Respimat for COPD

01-08-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimPharmaceuticalPulmonologyRegulationRespiratory and PulmonaryStriverdi RespimatUSA

Zealand and Boehringer link up to advance novel peptide medicines

Zealand and Boehringer link up to advance novel peptide medicines

28-07-2014

Denmark’s Zealand Pharma has entered into a new global exclusive licence and R&D collaboration with…

Boehringer IngelheimCardio-vascularDenmarkFinancialGermanyLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

24-07-2014

German family-owned drug major Boehringer Ingelheim has been accused of withholding ‘important analyses’…

Boehringer IngelheimDabigatranGermanyHematologyPharmaceuticalPradaxaPyridinesRegulationUKUniversity of California

Breast cancer market to grow to over $13 billion by 2020

Breast cancer market to grow to over $13 billion by 2020

23-07-2014

The increased use of targeted therapies, along with a greater uptake of branded drugs and rising incidence…

afatinibAfinitorBoehringer IngelheimBreast cancer therapeuticsEisaiEuropeGBI ResearchHalavenJapanMarkets & MarketingneratinibNorth AmericaNovartisOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

US breakthrough designation in IPF for Boehringer’s nintedanib

US breakthrough designation in IPF for Boehringer’s nintedanib

17-07-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation for German family-owned…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Bayer the latest in anticoagulant lawsuit action

Bayer the latest in anticoagulant lawsuit action

16-07-2014

German drug major Bayer is just one of the latest companies to be facing lawsuits over its anticoagulants,…

BayerBoehringer IngelheimHematologyHematologyLegalPharmaceuticalPradaxaRivaroxabanUSAWarfarin SodiumXarelto

French studies show oral anticoagulants do not cause an increased risk of severe hemorrhage despite recent deaths

French studies show oral anticoagulants do not cause an increased risk of severe hemorrhage despite recent deaths

15-07-2014

Four elderly French people who had taken Praxada to present strokes died of hemorrhages last year, although…

AnticoagulantsBoehringer IngelheimDabigatranFranceHealthcareHematologyLegalPharmaceuticalPradaxarivaroxabanVitamin K

Boehringer Ingelheim’s Pradaxa available in UK for DVT

Boehringer Ingelheim’s Pradaxa available in UK for DVT

15-07-2014

German family-owned drug major Boehringer Ingelheim says that Pradaxa (dabigatran etexilate) will be…

Boehringer IngelheimDeep vein thrombosisHematologyPharmaceuticalPradaxaRegulationUK

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

02-07-2014

The US subsidiary of German family-owned drug major Boehringer Ingelheim says that the New Drug Application…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

02-07-2014

German family-owned pharma major Boehringer Ingelheim says it has submitted Marketing Authorization Applications…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and Pulmonarytiotropium + olodaterol Respimat

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

26-06-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to idarucizumab, an…

Boehringer IngelheimCardio-vascularidarucizumabPharmaceuticalPradaxaRegulationResearchUSA

Boehringer Ingelheim pulls out of hepatitis C drug development

Boehringer Ingelheim pulls out of hepatitis C drug development

23-06-2014

German family-owned pharma major Boehringer Ingelheim revealed that, following a re-evaluation of its…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

1 to 25 of 184 results

Back to top